详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

5| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

研究疾病/适应症：

研究类型：

研究单位： [1]Daiichi Sankyo [2]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China,100021 [3]Peking University International Hospital,Beijing,China,100125 [4]Beijing Cancer Hospital,Beijing,China,100142 [5]Hunan Second People''s Hospital,Changsha,China,410007 [6]Fujian Cancer Hospital,Fuzhou,China,350014 [7]Affiliated Cancer Hospital and Institute of Guangzhou Medical University,Guangzhou,China,510060 [8]The First Affiliated Hospital of Sun Yat-sen University,Guangzhou,China,510062 [9]Zhejiang Cancer Hospital,Hangzhou,China,310022 [10]Anhui Provincial Cancer Hospital,Hefei,China,230031 [11]First Affiliated Hospital of Shandong First Medical University,Jinan,China,250014 [12]Cancer Hospital of Shandong First Medical University,Jinan,China,250103 [13]The First Affiliated Hospital of Jinzhou Medical University,Jinzhou,China,121001 [14]The First Affiliated Hospital of Nanchang University,Nanchang,China,330000 [15]Guangxi Medical University Cancer Hospital,Nanning,China,541000 [16]Ruijin Hospital, Shanghai Jiaotong University School Of Medicine,Shanghai,China,200025 [17]Zhongshan Hospital Fudan University,Shanghai,China,200032 [18]The First Hospital of China Medical University,Shenyang,China,110001 [19]Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center,Shenzhen,China,518116 [20]The Fourth Hospital of Hebei Medical University,Shijiazhuang,China,050011 [21]Shanxi Provincial Cancer Hospital,Taiyuan,China,030013 [22]The First Affiliated Hospital of Xiamen University,Xiamen,China,361102 [23]Henan Cancer Hospital,Zhengzhou,China,450052 [24]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China,450052

关键词： Locally advanced or metastatic NSCLC HER2 mutations T-DXd

研究目的：

Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations. This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.